Frampton, James E.
July 2011
CNS Drugs;2011, Vol. 25 Issue 7, p615
Academic Journal
Vilazodone, a novel antidepressant agent that combines selective serotonin reuptake inhibitor (SSRI) activity and serotonin 5-HT1A receptor partial agonist activity in a single molecule, is indicated for the treatment of major depressive disorder (MDD) in the US. It is administered orally, once daily, with food. At the recommended dosage of 40 mg/day, vilazodone was effective in the short-term treatment of MDD in adults, as evidenced by significant improvements versus placebo on multiple measures of depression, including the Montgomery-A sberg Depression Rating Scale (MADRS) and the 17-item Hamilton Rating Scale for Depression (HAM-D-17), in two pivotal, 8-week, randomized, double-blind, phase III studies. Significant differences between vilazodone and placebo on the MADRS and HAM-D-17 were seen after 1 week of treatment (first efficacy timepoint) in one of the two studies. Long-term treatment with vilazodone 40mg/day was associated with an improvement from baseline in depressive symptoms in a 52-week, noncomparative, phase III study. Vilazodone was generally well tolerated in the short- and long-term treatment of MDD, with diarrhoea and nausea being the most frequently occurring treatment-emergent adverse events. Vilazodone had a minimal impact on sexual functioning in the three phase III studies. INSET: Features and properties of vilazodone (ViibrydTM).


Related Articles

  • Drug Treatments for Patients with Dysthymia. Kripke, Clarissa // American Family Physician;10/1/2004, Vol. 70 Issue 7, p1269 

    Presents information on drug treatments that are effective for dysthymia. Comparison between the efficacy of anti-depressants and placebo; Information on the side effects of tricyclic antidepressants and selective serotonin reuptake inhibitors.

  • Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Peet, Malcolm; Peet, M // British Journal of Psychiatry;Apr94, Vol. 164, p549 

    The rate of treatment-emergent switch into mania has been calculated from all available clinical trial data on the selective serotonin re-uptake inhibitors (SSRIs) fluoxetine, fluvoxamine, paroxetine, and sertraline, relative to comparative groups treated with tricyclic antidepressants (TCAs) or...

  • Duloxetine: A Review of its Use in the Treatment of Major Depressive Disorder. Frampton, James E.; Plosker, Greg L. // CNS Drugs;2007, Vol. 21 Issue 7, p581 

    Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD).Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective...

  • The Future of Depression Psychopharmacology. Belmaker, Robert H. // CNS Spectrums: The International Journal of Neuropsychiatric Med;Aug2008, Vol. 13 Issue 8, p682 

    Along with the development of selective sertonin reuptake inhibitors there has been a tremendous widening of the definition of depression and an impressive decrease in the placebo-drug difference in controlled studies. In the early 1960s, about one third of depressed patients improved with...

  • Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion. Abler, Birgit; Seeringer, Angela; Hartmann, Antonie; Grön, Georg; Metzger, Coraline; Walter, Martin; Stingl, Julia // Neuropsychopharmacology;Aug2011, Vol. 36 Issue 9, p1837 

    Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs) like paroxetine in the treatment of depression, imposing a considerable risk on medication adherence and hence therapeutic success. Bupropion, a norepinephrine and dopamine reuptake inhibitor, is...

  • Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. Garnock-Jones, Karly P.; McCormack, Paul L. // CNS Drugs;2010, Vol. 24 Issue 9, p769 

    Escitalopram (escitalopram oxalate; Cipralex®, Lexapro®), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting...

  • A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future. Taylor, Warren D.; Doraiswamy, P. Mural // Neuropsychopharmacology;Dec2004, Vol. 29 Issue 12, p2285 

    Depression in the elderly is a major public health problem as untreated depression adversely impacts comorbid illnesses. It is important to develop safe and effective antidepressant therapies for older individuals. We performed a systematic review of all published randomized, placebo-controlled...

  • SSRIs start to relieve depression soon after the start of treatment.  // BMJ: British Medical Journal (International Edition);12/9/2006, Vol. 333 Issue 7580, p1180 

    The article examines how long it takes for selective serotonin reuptake inhibitors (SSRIs) to relieve depression and focuses on a study which looked at published clinical trials that compared SSRI antidepressants with placebo for depressed patients. The authors found that antidepressants work...

  • Initial Effectiveness, Partial Remission, and Full Remission in Depression: Focus on Long-Term Treatment with SNRIs. Dursun, Serdar // CNS Spectrums: The International Journal of Neuropsychiatric Med;Jul2008 Supplement 11, Vol. 13 Issue 7, p10 

    Full remission, defined as the absence of all significant symptoms of depression over at least 6 months, is the ultimate goal of antidepressant therapy. Remission takes time and studies have shown that remission rates continue to rise for at least 3 months after initial improvement. Depression...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics